Botanix Defers API Purchases and Moves to De-Risk Sofdra Supply Chain

Botanix Pharmaceuticals Limited ( (AU:BOT) ) has shared an announcement.

Botanix Pharmaceuticals has renegotiated its active pharmaceutical ingredient supply agreement with Kaken Pharmaceutical, pushing major Sofpironium Bromide purchases scheduled for April 2026 and January 2027 out to December 2027 and December 2028, leaving no further API buys required before late 2027. The company also retains three additional API purchase commitments for 2029 and 2030, each around US$7.5 million, preserving a long-term supply framework for its lead product Sofdra.

In parallel, Botanix is advancing plans to qualify an additional API supplier for Sofpironium Bromide to de-risk its supply chain and potentially cut cost of goods sold by 25–40%, which would support higher gross margins. Management says the deferral of near-term purchases, combined with proceeds from its current capital raise if it goes ahead, should improve working capital flexibility and strengthen the company’s capacity to execute its commercial rollout of Sofdra and expansion of its fulfilment platform.

The most recent analyst rating on (AU:BOT) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.

More about Botanix Pharmaceuticals Limited

Botanix Pharmaceuticals Limited is a commercial dermatology company based in Philadelphia and Phoenix that has received FDA approval for Sofdra, a treatment for primary axillary hyperhidrosis. Sofdra is the first and only new chemical entity approved by the FDA for this condition, targeting patients who have had limited options for managing excessive underarm sweating.

Average Trading Volume: 12,102,932

Technical Sentiment Signal: Sell

Current Market Cap: A$90.94M

See more data about BOT stock on TipRanks’ Stock Analysis page.